Log In
BCIQ
Print this Print this
 

OCU200

  Manage Alerts
Collapse Summary General Information
Company Ocugen Inc.
DescriptionAngiogenic tumstatin fusion protein
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/05/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today